Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy

AIDS

Volumn 15, Issue 9, 2001, Pages 1115-1123

  Poundstone, Katharine E ^a   Chaisson, Richard E ^a   Moore, Richard D ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; HIV progression; Injecting drug use; Sex

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; DEATH; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; SEX DIFFERENCE; SURVIVAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; URBAN POPULATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; RISK FACTORS; SEX FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES;

EID: 0035876449     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200106150-00006     Document Type: Article

References (30)

1. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society - USA Panel
2. Natural history of HIV infection in the era of combination antiretroviral therapy
3. Changing patterns of mortality across Europe in patients infected with HIV-1
4. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
5. The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs
6. Marked declines in human immunodeficiency virus-related mortality in Chicago in women, African Americans, Hispanics, young adults, and injection drug users, from 1995 through 1997
7. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration
8. Racial differences in the use of drug therapy for HIV disease in an urban community
9. Variations in the care of HIV-infected adults in the United States. Results from the HIV Cost and Services Utilization Study
10. Impact of zidovudine on the natural history of acquired immune deficiency syndrome
11. Impact of antiretroviral combination therapies on AIDS surveillance reports in Switzerland
12. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens
13. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
14. A comparison of exposure groups in the EuroSIDA Study: Starting highly active antiretroviral therapy (HAART), response to HAART, and survival
15. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy
16. Changes in survival among people with AIDS in Lazio, Italy from 1993 to 1998
17. Race, sex, drug use, and progression of human immunodeficiency virus disease
18. Understanding the clinical and economic outcomes of HIV therapy: The Johns Hopkins HIV Clinical Practice Cohort
19. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome
20. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
21. Use of cohort studies for evaluating AIDS therapies
22. The robust inference for the Cox proportional hazards model
23. Self-reported antiretroviral therapy in injection drug users
24. Barriers to use of free antiretroviral therapy in injection drug users
25. Antiretroviral use and adherence predicted by active illicit drug use
26. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
27. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection. The Swiss HIV Cohort Study
28. Effect of HCV infection on HIV disease progression and survival among HIV-infected adults